Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? results from a Swedish cohort

Arthritis Care and Research

Volumn 66, Issue 2, 2014, Pages 173-179

  Kristensen, Lars Erik ^a,b   Bliddal, Henning ^a   Christensen, Robin ^a   Karlsson, Johan A ^b   Gülfe, Anders ^b   Saxne, Tore ^b   Geborek, Pierre ^b  

^a LUND UNIVERSITY   (Sweden)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE MARKER; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RHEUMATOID ARTHRITIS; SWEDEN; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; JOINTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; REGISTRIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893429521     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22107     Document Type: Article

References (27)

1. Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
2. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
3. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
4. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1999; 130: 478-86.
5. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
6. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
7. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
8. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
9. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biologics or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274-9.
10. Geborek P, Crnkic M, Petersson IF, Saxne T,. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
11. Kristensen LE, Saxne T, Nilsson JA, Geborek P,. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.
12. Hyrich KL, Watson KD, Silman AJ, Symmons DP,. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
13. Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Soderlin MK, Geborek P,. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established rheumatoid arthritis: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 495-9.
14. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al, on behalf of all departments of rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
15. Ellegaard K, Christensen R, Torp-Pedersen S, Terslev L, Holm CC, Konig MJ, et al. Ultrasound Doppler measurements predict success of treatment with anti-TNFα drug in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford) 2011; 50: 506-12.
16. Atzeni F, Cazzola M, Benucci M, Di Franco M, Salaffi F, Sarzi-Puttini P,. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 2011; 25: 165-71.
17. Schaible HG, von Banchet GS, Boettger MK, Brauer R, Gajda M, Richter F, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2010; 1193: 60-9.
18. Wolfe F, Michaud K,. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004; 31: 695-700.
19. Kapoor SR, Hider SL, Brownfield A, Mattey DL, Packham JC,. Fibromyalgia in patients with rheumatoid arthritis: driven by depression or joint damage? Clin Exp Rheumatol 2011; Suppl 69: S88-91.
20. Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B,. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 2004; 43: 1504-7.
21. Van Riel PL, van Gestel AM, Scott DL, on behalf of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials. The EULAR handbook of clinical assessment in rheumatoid arthritis. Alpen an den Rijn (The Netherlands): Van Zuiden Communications; 2000.
22. Kristensen LE, Saxne T, Geborek P,. The Lundex, a new index for evaluating tumor necrosis factor blockers in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600-6.
23. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort. Arthritis Care Res (Hoboken) 2011; 63: 1672-9.
24. Aletaha D, Ward MM,. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006; 65: 227-33.
25. Wolfe F, Michaud K, DeWitt EM,. Why results of clinical trials and observational studies of antitumor necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; Suppl II: ii13-7.
26. Pincus T, Sokka T,. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004; Suppl II: ii32-9.
27. Pincus T, Sokka T,. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Baillieres Best Pract Res Clin Rheumatol 2001; 15: 139-70.